Johannesburg, 24 March 2023 – The Unitaid-funded IMPAACT4TB Consortium, led by the Aurum Institute, announced today that it will provide 250,000 patient courses of short course rifapentine-based preventive treatment regimens to seven countries to help prevent tuberculosis (TB). The patient courses will include the three-month 3HP regimen, and the even shorter 1HP, that is only taken for 28 days. This contribution is part of the Consortium’s ongoing efforts to end TB and improve global health outcomes. 

Partners announce two new agreements to lower the price of rifapentine-based treatments to prevent TB in low- and middle-income countries.

The #RightToPreventTB campaign focuses attention on the urgent need to scale-up TB preventive treatment as a matter of human rights.

As the Unitaid-funded ASCENT project launches the main research phase, investigating the effectiveness of digital adherence technologies and data-driven support interventions on TB treatment completion and success rates, Unitaid asked the researchers leading the study to tell more about their work and its potential impact.

The Hague / Geneva, 4 August 2021 – A large global study which aims to determine if digital adherence technologies (DATs) can provide more patient-friendly approaches to improve tuberculosis (TB) treatment outcomes launches in Ethiopia, Tanzania, South Africa, the Philippines and Ukraine, as part of the ASCENT project.

Geneva, 30 January 2020 – Unitaid will invest US$ 39 million in two projects to speed up the development of long-acting versions of medicines for low- and middle-income countries. Innovative ways to administer drugs, which have revolutionized contraception and the treatment of schizophrenia, could redefine prevention and treatment of infectious diseases, but remain at early stages of research because of market barriers.

Hyderabad, India – Unitaid and partners launched a trio of innovations today (November 1) that will work together to fight tuberculosis through gene-based diagnosis, better treatments and ingenious technologies that help patients remember to take their medicines.

Geneva, 23 July 2019 – The KNCV Tuberculosis Foundation and Unitaid signed a US$ 13.9 million grant agreement on Tuesday to increase the use of smart pillboxes and mobile technology, aiming to help patients adhere to their medicines and raise the world’s plateauing cure rates for TB.

Geneva – The Foundation for Innovative New Diagnostics (FIND) and Unitaid signed a US$ 14.5 million grant Thursday (July 4) to deploy a powerful new technology in the diagnosis of drug-resistant tuberculosis.

Geneva, 29 May 2019 –Unitaid and UNICEF will collaborate to save the lives of more children, adolescents and mothers, an agreement formalized by a memorandum of understanding signed today.